UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO) exercised 9,500 stock options and sold 9,500 United Therapeutics (UTHR) common shares held by a family trust for roughly $5 million in total proceeds under a 10b5‑1 trading plan.

On August 5, 2026, United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired an equal number of common shares, then sold all 9,500 resulting shares the same day in a series of open‑market transactions at prices ranging from approximately $502 to $525 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. The gross sale proceeds from these 9,500 shares were roughly $4.9–$5.0 million, implying a spread of about $3.5–$3.7 million over the aggregate option exercise cost, and after these trades the reporting person (through various family trusts and related holdings) continued to beneficially own over 300,000 shares of United Therapeutics common stock indirectly, plus additional directly held and spousal holdings, representing a substantial continuing equity interest.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000114

Alert Tier

7